The ChristianaCare Gene Editing Institute is at the forefront of advancing CRISPR gene editing technologies aimed at improving human health, particularly in the treatment of solid tumors and genetic diseases. Their innovative approach includes the development of a novel lung cancer therapy that utilizes CRISPR for the first time in solid tumors, showcasing their commitment to translating scientific discoveries into effective treatments. The Institute's focus on translational sciences is supported by a collaborative team of gene scientists and oncologists, who are dedicated to creating life-extending solutions for patients facing serious health challenges.

Among the Institute's key technological advancements is DECODR™, a powerful tool designed to streamline the analysis of CRISPR edits in Sanger sequencing data. Recognized for its user-friendly interface and computational efficiency, DECODR™ allows researchers to quantify various types of genetic edits without limitations on the size of insertions or deletions. This tool not only accelerates the research process but also enhances the precision of gene editing, making it a valuable resource for both academic and non-profit researchers. The Gene Editing Institute continues to innovate and provide essential tools that empower researchers to tackle complex genetic disorders and improve therapeutic outcomes.

United States

Gene Editing Institute V1 is a biotechnology company that advances the power of CRISPR gene editing technology to improve human life through groundbreaking research and development.

Gene Editing Institute V1

Company Details